Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06667076 · ClinicalTrials.gov registry record · Phase 2

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 2
Development phase
480
Enrollment target
20
Study locations

NCT06667076 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 480 participants, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06667076, a Phase 2 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 2
Development phase
480 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Amivantamab
  • DRUG Lazertinib
  • DRUG Chemotherapy: Pemetrexed
  • DRUG Chemotherapy: Carboplatin

Study Locations (20)

California

  • The Oncology Institute of Hope and Innovation - Cerritos
  • City of Hope Corona - Corona
  • City of Hope - Duarte
  • Providence Medical Foundation - Fullerton
  • Oncology Physicians Network Healthcare - Glendale
  • Los Angeles Cancer Network - Glendale
  • Glendale Adventist Medical Center - Glendale
  • Marin Cancer Center - Greenbrae
  • City of Hope Seacliff - Huntington Beach
  • City of Hope Orange County Lennar Foundation Cancer Center - Irvine
  • University of California San Diego Health - La Jolla
  • City of Hope Antelope Valley - Lancaster
  • City of Hope Long Beach Elm - Long Beach
  • Cancer and Blood Specialty Clinic - Los Alamitos
  • USC Norris Comprehensive Cancer Center - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles
  • Valkyrie Clinical Trials - Los Angeles

Alabama

  • Southern Cancer Center, PC - Daphne
  • Clearview Cancer Institute - Huntsville

Arizona

  • City of Hope Phoenix - Goodyear

Trial Details

FieldValue
Enrollment Target 480 participants
Start Date 2024-12-16
Est. Completion 2030-12-26
Phase Phase 2

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06667076

The ClinicalTrials.gov registry entry for NCT06667076 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (50% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 4 interventions - of which Amivantamab is the first listed.

NCT06667076 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT06667076 about?

NCT06667076 is a clinical study titled "A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)". The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of ...

What is the current status of trial NCT06667076?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 480 participants. The study started on 2024-12-16. Estimated completion is 2030-12-26.

What conditions does trial NCT06667076 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT06667076?

The interventions under investigation include: Amivantamab (DRUG), Lazertinib (DRUG), Chemotherapy: Pemetrexed (DRUG), Chemotherapy: Carboplatin (DRUG).

Who is sponsoring clinical trial NCT06667076?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06667076 being conducted?

This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.